Vertex Pharma downgraded by Wolfe Research
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Wolfe Research downgraded Vertex Pharma from Outperform to Peer Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2025 | Outperform → Peer Perform | Wolfe Research | |
| 5/6/2025 | $503.00 | Outperform → Market Perform | Leerink Partners |
| 4/22/2025 | $535.00 | Overweight | Cantor Fitzgerald |
| 2/12/2025 | $408.00 → $424.00 | Sell → Hold | Canaccord Genuity |
| 2/11/2025 | Sell → Hold | Canaccord Genuity | |
| 1/30/2025 | $460.00 | Overweight → Equal Weight | Wells Fargo |
| 12/20/2024 | $600.00 → $535.00 | Buy | H.C. Wainwright |
| 12/19/2024 | Outperform → Perform | Oppenheimer |